MCMichael Christensen

Michael Christensen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Michael Christensen has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Temporal glomerular gene expression dynamics during disease progression in a mouse model of hypertension‐accelerated diabetic kidney disease

    by Adam B. Marstrand‐Jørgensen, Frederikke Emilie Sembach, Maria Ougaard, Ditte Hansen, Mette Viberg Østergaard, Henrik H. Hansen, Louise S. Dalbøge, Ole Jørgen Kaasbøll, Michael Christensen

    Background: The current understanding of diabetic kidney disease (DKD) has significant gaps regarding the underlying pathogenesis. In this study, we aimed to characterize the temporal progression of DKD using a state‐of‐the‐art mouse model of hypertension‐accelerated disease, integrating kidney biomarker analysis, histopathology, and glomerular transcriptomic profiling. Methods: Female diabetic db/db mice received a single intravenous dose of adeno‐associated virus‐mediated renin overexpression (ReninAAV, week 5) and underwent uninephrectomy (UNx, week 4). db/db UNx‐ReninAAV mice were terminated at weeks 1, 4, 8, and 12 ( n = 7–8 per group). Female db / m mice were used as healthy controls. Study endpoints included plasma and urine biochemistry, glomerulosclerosis scoring, quantitative kidney histology, and RNA sequencing of glomeruli isolated using laser‐capture microdissection. Results: db/db UNx‐ReninAAV mice developed progressive albuminuria (from week 4) and glomerulosclerosis (from week 8). A pathway analysis of clustered gene regulations revealed broad glomerular transcriptome perturbations with signatures of increased extracellular matrix (ECM) turnover from week 8 and early onset of metabolic dysfunction. Markers of glomerular cell types and injury exhibited temporal regulation over the course of DKD, with early and sustained downregulation of endothelial markers, heterogeneous regulation of podocyte markers, and significant mesangial and parietal epithelial aberrations. Furthermore, the upregulation of cell injury markers confirmed progressive glomerular injury in the model. Conclusion: The db/db UNx‐ReninAAV mouse model exhibits distinct temporal dynamics in glomerular cell markers, metabolic dysregulation, ECM remodeling, and injury. Together, these results highlight the utility of the db/db UNx‐ReninAAV model as a relevant preclinical platform for studying progressive DKD.


  • Open Access

    Nephroprotective Effects of Semaglutide as Mono- and Combination Treatment with Lisinopril in a Mouse Model of Hypertension-Accelerated Diabetic Kidney Disease

    by Louise S. Dalbøge, Michael Christensen, Martin Rønn Madsen, Thomas Secher, Nicole Endlich, Vedran Drenic’, Alba Manresa-Arraut, Henrik H. Hansen, Ida Rune, Lisbeth N. Fink, et al.

    Background: Obesity, hyperglycemia and hypertension are critical risk factors for development of diabetic kidney disease (DKD). Emerging evidence suggests that glucagon-like peptide-1 receptor (GLP-1R) agonists improve cardiovascular and renal outcomes in type 2 diabetes patients. Here, we characterized the effect of the long-acting GLP-1R agonist semaglutide alone and in combination with an ACE inhibitor (lisinopril) in a model of hypertension-accelerated, advanced DKD facilitated by adeno-associated virus-mediated renin overexpression (ReninAAV) in uninephrectomized (UNx) female diabetic db/db mice. Methods: Female db/db mice received a single intravenous injection of ReninAAV 1 week prior to UNx. Six weeks post-nephrectomy, db/db UNx-ReninAAV mice were administered (q.d.) vehicle, semaglutide (30 nmol/kg, s.c.) or semaglutide (30 nmol/kg, s.c.) + lisinopril (30 mg/kg, p.o.) for 11 weeks. Endpoints included blood pressure, plasma/urine biochemistry, kidney histopathology and RNA sequencing. Results: Vehicle-dosed db/db UNx-ReninAAV mice developed hallmarks of DKD characterized by severe albuminuria and advanced glomerulosclerosis. Semaglutide robustly reduced hyperglycemia, hypertension and albuminuria concurrent with notable improvements in glomerulosclerosis severity, podocyte filtration slit density, urine/renal kidney injury molecule-1 (KIM-1) levels and gene expression markers of inflammation and fibrogenesis in db/db UNx-ReninAAV mice. Co-administration of lisinopril further ameliorated hypertension and glomerulosclerosis. Conclusions: Semaglutide improves disease hallmarks in the db/db UNx-ReninAAV mouse model of advanced DKD. Further benefits on renal outcomes were obtained by adjunctive antihypertensive standard of care. Collectively, our study supports the development of semaglutide for management of DKD.